Tarsus Pharmaceuticals, Inc. TARS Lease Liability Payments - Due Year Four
Lease Liability Payments - Due Year Four at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s lease liability payments - due year four.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s lease liability payments - due year four?
- Tarsus Pharmaceuticals, Inc. (TARS) reported lease liability payments - due year four of $2.87M in Q1 2026.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s lease liability payments - due year four?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s lease liability payments - due year four has grown at a 156.6% compound annual growth rate (CAGR), from $25K to $2.78M.
- What does lease liability payments - due year four mean?
- The contractual cash obligations for operating and finance leases due in the fourth year following the balance sheet date. This is part of the long-term lease maturity schedule that helps investors assess the company's future fixed cost burden. It allows for better modeling of long-term capital allocation and cash flow stability.